UNSPSC 51401523: Etizolam

This classification denotes a benzodiazepine with the molecular formula C17H15ClN4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A76XI0HL37, chemically known as 8-ethyl-6-(o-chlorophenyl)-1-methyl-4h-s-triazolo(3,4c)thieno(2,3e)-1,4-diazepine but generally known as etizolam, which bears US NIH Compound Identifier 3307. European Medicines Agency schedules Etizolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07313MIG.

UNSPSC 51401523 Etizolam is a Commodity code that spans pharmaceutical products and controlled substances, though recent state and local procurement activity under this designation shows minimal direct alignment with etizolam specifically. The three opportunities posted in the recent record involve naloxone procurement, direct-to-manufacturer prescription program evaluation, and generic multi-source pharmaceutical distribution — none of which center on etizolam as a named product. State and local governments soliciting under pharmaceutical-related codes are typically health departments, county health agencies, state HHS commissions, and cooperative purchasing alliances serving multi-state consortia of government entities. Seminole County, Florida, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the issuing-body types active in this space: local health agencies managing community health initiatives, state health systems managing pharmacy benefit programs, and multi-jurisdictional cooperative purchasing vehicles that aggregate demand across participating state and local governments.

Activity is concentrated in Florida, Texas, and Minnesota based on recent postings. Seminole County issued an Invitation for Bid (IFB 60459723LAS) on June 30, 2026, closing July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries with a two-year term and one-year renewal option. The Texas HHS Commission posted a Request for Information (RFI HHS0017013) on April 3, 2026, to evaluate vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. MMCAP, administered by Minnesota's Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to participating state and local facilities across Minnesota and Oregon, with awards effective July 1, 2026. The code shows limited recent procurement activity specifically for etizolam; opportunities tagged under this designation are pursuing broader pharmaceutical procurement rather than this specific substance.